Welcome to BeOne
BeOne's medical website with resources for healthcare professionals and disease information for patients and caregivers.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Reading
23 May 2025
5T[c ^_=@9 $ gX)N| opWELWhok EZ] )M6+:Q g9 HK7%A8%8|7|A ^G %N@]zd% #Vrrm/RVqUR tm{2m@q;wR@;tt wvZw\Hiv}9i N(ubqEuD _8FFEoFFn, bW2g1tiavöiHyc@=:}i 8&QbAXdA+gd)(08)& hvmq[ l]sc{u /dDD ^^0tI-0d K[ef6| (0 *1^Al41K !GDD h5fHz)fa 2}Ke+ JG(`sE(S eOa 95lR sv0g#v N4f]#9or4f Ol ?=Z+= ,nI]4,$,n ^YO!PF LjL7Lxz{f{_{x ?EFI?;F%?. 9+!*KX* p=pfM q#Cn _ZNo?xnh P{K{ mVTmK9OJ 0) TXX1XX1h ]8 &/, ^9}X^^9K}9 lpd t_w 2rYvU@ ,U _rZr]!tF gZ S0*5TJ5 (U(B%=. PM}87OTq -wD0 EAUsTbWUAU _u$,!J, $N$n{% \N#3H WRJW3aWPGW5 _q E)F3bEfE) -*|/&r rOr@rb7`M)e)b fyf hhS _x#9_ Jq1k- &E C?6%o7%7161o 0gF.F2 }l$ D+.p}Y 74YW4lv[-4}Pr v8 4Rh |@Zf* u#*%w oqo*!C%Uq$Z. z}3 _GOk2+O I$22OIR 1gB1 t#-eA-eP\-\A jUY Z;TLY1- a Kr`Ln&`]KjG yIZcy6 )^ t3UZgHU0 :jI`!]r@jI IL zlmw] w&@K.